Greater Paris Metropolitan Region
I am a passionate scientist with 8 years of experience in cancer research. Following a PhD focused on cancer-targeted therapy (specifically in pancreatic cancer), I shifted my interest to immuno-oncology. My postdoctoral project aimed to enhance CAR T-cell therapy by using a CRISPR genome wide screen. Today, I am working to make T-cell based therapies universal through the allogenic strategy. Alongside my strong technical and organizational skills, I have significant experience in mentoring junior team members.
With my team (CRRET) we are studying the role of nucleolin in pancreatic ductal adaenocarcinoma(PDAC). This protein is expressed on the surface of proliferative cells and overexpressed in cancer, so it's a promising diagnostic marker and therapeutic target. My team synthetized N6L, a nucleolin antagonist, that can inhibit proliferation and trigger apoptosis of different cancers in vitro and in vivo. Moreover our molecule passed the Phase I of clinical trials and we are preparing it for the Phase II. My clinical aim is to find the best protocol to start the Phase II. For this I will test different combination treatments (N6L+other drugs) in different human PDAC cells, murin models and human derived PDAC organoids. My basic aim is to discover new surface molecular interactors of nucleolin in PDAC cells in order to find new markers and to clarify N6L action mechanism. Bisides, I work for other projects with collaborators with which we have already published 2 papers.